Introduction
============

Breast cancer is the most common cancer among women. Globally, 1.67 million women were diagnosed with breast cancer in 2012, contributing to more than 25% of female cancer incident cases.[@R1] The incidence of breast cancer among Chinese women is increasing twice as fast as the global rate.[@R2] In China, breast cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths.[@R3]

Breast cancer is a potentially curable disease if diagnosed and treated at an early stage. The Surveillance, Epidemiology, and End Results Programme reported that women diagnosed with breast cancer at an early stage (Stage I or II) have a better prognosis (5-year survival rate, 85--98%) than for advanced breast cancer (5-year survival rate for Stage III or IV, 30--70%).[@R4] The strong argument for earlier diagnosis with respect to patient outcome has resulted in the initiation of breast cancer screening programmes in many countries. The aims of such programmes are the early diagnosis and treatment of cancer patients to improve disease outcomes and to reduce mortality.[@R5]

Although population-based mammography has been widely adopted in high-income countries for more than 30 years,[@R6] it is less cost--effective in low- and middle-income countries.[@R7] Studies in China,[@R8]^--^[@R10] Ghana[@R11] and the Islamic Republic of Iran[@R12]^,^[@R13] have revealed that population-based mammography is not economically attractive. However, a high-risk population-based breast cancer screening programme could contribute to a much higher detection rate[@R14]^--^[@R16] and could therefore be good value for money in low- and middle-income countries.

Experts have recommended ultrasound as an adjunct to mammography among high-risk women.[@R17]^--^[@R20] For patients with dense breasts, non-calcified breast cancers are more likely to be missed by mammography;[@R21] ultrasound permits the detection of small, otherwise occult, breast cancer.[@R22]

In 2012, the Government of China launched a cancer screening programme in 14 cities to screen common cancers, including breast cancer. Our objective was to provide policy-makers with economic information regarding the cost--effectiveness of breast cancer screening for high-risk women. In this paper, we used a Markov model to compare the lifetime effects, costs and cost--effectiveness of breast cancer screening, versus no screening, using published data from this programme ([Fig. 1](#F1){ref-type="fig"}).
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Methods
-------

### Screening strategy

To measure the individual risk of breast cancer, health professionals invited women aged 40--69 years to health facilities and used paper-based questionnaires to collect information on individual breast cancer exposure. The health professionals then used the Harvard Cancer Index online tool, now called Your Disease Risk, to process the collected information.[@R23]^,^[@R24] The tool calculates individual cancer scores, by giving risk scores to exposures, including family history, height, age of first period, age of first birth, number of births, age at menopause, use of oral contraceptives, estrogen replacement, Jewish heritage (i.e. higher prevalence of *BRAC1/2* gene mutations) and exposure to ionizing radiation. A total of 198 097 women completed a risk assessment questionnaire during 2012--2013; 17 104 were identified as being at high risk of developing breast cancer.[@R14]

The programme working group estimated the population average score based on the prevalence of risk factors among the Chinese population, and adjusted according to China's cancer epidemiology data over 20 years.[@R14] The relative risk was obtained by comparing the individual risk score with the population average. Women with a relative risk of \> 2 are defined as being at high risk. The programme screens high-risk women aged 40--44 years by ultrasound and the women with suspected results are further examined by mammography. Women with a suspicious mammography result are tested by biopsy for diagnostic confirmation. The programme screens high-risk women aged 45--69 years by both mammography and ultrasound, and suspected results from either method are confirmed with biopsy.

For low-risk women, breast cancer is only diagnosed on presentation of symptoms. Breast cancer patients in the screening arm can be diagnosed while still asymptomatic, that is, at an earlier stage of the disease when prognosis is better.

### Modelling strategy

[Box 1](#B1){ref-type="boxed-text"} presents our model assumptions. We adapted a prior natural history Markov model[@R8] using the TreeAge software (TreeAge software Inc. Williamstown, United States of America), to inform a long-term decision model. Our model predicted the lifetime costs and quality-adjusted life years (QALYs) of screening and no screening for Chinese urban women with no previous history of breast cancer, from age 40 years to death. We used an annual screening frequency as the baseline, and we explored the scenarios of screening every 3 and 5 years.

###### Model assumptions for estimating cost--effectiveness ratios of risk-based breast cancer screening programme in urban China

#### Parameters

-   For progression rates between disease stages and relative risk of invasive cancer in ductal carcinoma in situ, we obtained data from other countries and assumed the parameters were applicable to China. We also used disutility score of screening from United Kingdom of Great Britain and Northern Ireland in the baseline analysis. However, we explored the uncertainty in the sensitivity analyses.

-   We assumed the risk of developing breast cancer among high-risk women was twice as much as the general population, based on the minimum threshold in Harvard Cancer Index (now called Your Disease Risk).

#### Model structure

-   We assumed patients at stage I can progress to stage II, stage III and stage IV. All women can die from non-breast cancer causes during disease progression, but only patients at stage IV can die from breast cancer.

-   We assumed all women with suspicious screening findings either with mammography or ultrasound proceeded to diagnostic biopsy. This follows the protocol of the Cancer Screening Programme in Urban China.

-   In the base-case analysis, we assumed all breast cancer patients diagnosed by biopsy received treatment. However, because uptake of treatment is uncertain, we explored the scenario where only 70% of detected breast cancers received treatment.

### Natural history

[Fig. 2](#F2){ref-type="fig"} illustrates the various health states and the potential transitions between them.[@R8] Healthy women can transition to ductal carcinoma in situ or stage I cancer, or remain free of cancer. Women with ductal carcinoma in situ are at a higher risk of developing invasive breast cancer (relative risk: 2.02).[@R4] Patients at stage I can progress to stage II, stage III and stage IV in turn. All women can die from causes other than breast cancer during disease progression, but only patients at stage IV can die from breast cancer. The state progression transition probabilities used in this analysis are from models described in the literature.[@R8]^,^[@R25]

![Natural history model for breast cancer progression, China](BLT.18.207944-F2){#F2}

We estimated the probability of symptoms in an unscreened population by calibrating the model as follows. In the non-screening arm, incident cases are only detected on presentation with symptoms; the distribution of incidence cases by stage is therefore a function of the probability of transitions and the probability of symptoms.[@R26] We adjusted the probability of symptoms until the distribution of cases presented at each stage was similar to the distribution of reported incidence cases.[@R3]^,^[@R27] Our estimates of transition probabilities are provided in [Table 1](#T1){ref-type="table"}.

###### Parameter values for modelling cost--effectiveness of risk-based breast cancer screening programme launched in 2012 in urban China

  Variables                                                     Baseline    Minimum   Maximum   Distribution   Reference/source
  ------------------------------------------------------------- ----------- --------- --------- -------------- -------------------------------------------------
  **Disease state progression transition probabilities**                                                       
  Age-specific incidence, years                                                                                
    40--44                                                      0.0006100   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    45--49                                                      0.0010056   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    50--54                                                      0.0011650   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    55--59                                                      0.0011179   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    60--64                                                      0.0010458   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    65--69                                                      0.0009782   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    70--74                                                      0.0009912   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    75--79                                                      0.0009067   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    80--84                                                      0.0007803   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
    ≥ 85                                                        0.0006430   --        --        --             Chinese Cancer Registry Annual Report[@R3] 
  Ratio of DCIS incidence to invasive breast cancer incidence   0.12        --        --        --             Lu et al.[@R28]
  RR of invasive cancer from DICS                               2.02        --        --        --             SEER Program[@R4]
  Progression rate                                                                                             
    Stage I--Stage II                                           0.06        --        --        --             Tsokos & Oğuztöreli[@R25] 
    Stage II--Stage III                                         0.11        --        --        --             Tsokos & Oğuztöreli[@R25] 
    Stage III--Stage IV                                         0.15        --        --        --             Tsokos & Oğuztöreli[@R25] 
    Stage IV--death                                             0.23        --        --        --             Wong et al.[@R8]
  Stage-specific probability of symptoms                                                                       
    Stage I                                                     0.004       --        --        --             Model calibration
    Stage II                                                    0.014       --        --        --             Model calibration
    Stage III                                                   0.380       --        --        --             Model calibration
    Stage IV                                                    0.980       --        --        --             Model calibration
  Annual fatality rate after treatment                                                                         
    Stage I                                                     0.006       --        --        --             Ginsberg et al.[@R27]
    Stage II                                                    0.042       --        --        --             Ginsberg et al.[@R27]
    Stage III                                                   0.093       --        --        --             Ginsberg et al.[@R27]
    Stage IV                                                    0.275       --        --        --             Ginsberg et al.[@R27]
  **Effectiveness of screening**                                                                               
  Ultrasound followed by mammography if required^a^                                                            
    Sensitivity                                                 0.848       0.681     0.949     Beta           Huang et al.[@R29]
    Specificity                                                 0.994       0.990     0.996     Beta           Huang et al.[@R29]
  Ultrasound and mammography^b^                                                                                
    Sensitivity                                                 0.939       0.798     0.993     Beta           Huang et al.[@R29]
    Specificity                                                 0.980       0.975     0.985     Beta           Huang et al.[@R29]
  **Utility scores**                                                                                           
    Stage I                                                     0.79        0.77      0.80      Log-normal     Shi et al.[@R30]
    Stage II                                                    0.79        0.78      0.80      Log-normal     Shi et al.[@R30]
    Stage III                                                   0.77        0.76      0.79      Log-normal     Shi et al.[@R30]
    Stage IV                                                    0.69        0.65      0.72      Log-normal     Shi et al.[@R30]
  Disutility from false-positive                                0.25        0.11      0.34      Log-normal     Peasgood et al.[@R31]
  **Costs, US\$**                                                                                               
  Questionnaire                                                 1.6         1.1       2.1       Gamma          Cancer Screening Programme in Urban China[@R32]
  Screening                                                     85.5        59.8      111.1     Gamma          Cancer Screening Programme in Urban China[@R32]
  Biopsy                                                        45.6        31.0      59.3      Gamma          Cancer Screening Programme in Urban China[@R32]
  Treatment costs                                                                                              
  DCIS                                                          2435        1705      3166      Gamma          Li et al.[@R33]
    Stage I                                                     10 067      7047      13 087    Gamma          Liao et al.[@R34]
    Stage II                                                    11 068      7748      14 388    Gamma          Liao et al.[@R34]
    Stage III                                                   12 867      9007      16 727    Gamma          Liao et al.[@R34]
    Stage IV                                                    17 766      12 436    23 096    Gamma          Liao et al.[@R34]

DCIS: ductal carcinoma in situ; US\$: United States dollars.

^a^ For women aged 40--44 years.

^b^ For women aged 45--69 years.

We assumed that all suspected cases proceeded to biopsy and that all diagnosed cases received treatment at baseline. We also explored a scenario of only 70% treatment uptake.

### Epidemiological and clinical data

We obtained the age-specific invasive breast cancer incidences from the 2012 Chinese Cancer Registry Annual Report.[@R3] Since ductal carcinoma in situ incidence is not recorded locally, we estimated the proportion of ductal carcinoma in situ among all breast cancer incidence cases from a Chinese study of 3838 patients.[@R28] We calculated age-specific mortalities from other causes by subtracting age-specific breast cancer mortality rates[@R35] from the corresponding age-specific all-cause mortality rates.[@R36]

### Costs

Data describing the costs of questionnaire, screening (whether ultrasound followed by mammography if required or ultrasound plus mammography, depending on age) and biopsy were available from the screening programme.[@R32] We also obtained the treatment costs by stage from the study by the programme working group;[@R34] such treatment cost data were estimated from 2746 invasive breast cancer patients from 37 hospitals across 13 provinces in China, comprising direct medical costs, direct non-medical costs and indirect costs. We used the disposable income per capita of Chinese urban residents (22.5 United States dollars (US\$) per day)[@R37] and productivity loss days to calculate the indirect costs. The Chinese screening programme did not report treatment costs for women with ductal carcinoma in situ, so we estimated these costs from a study of 211 Sichuan Cancer Hospital patients.[@R33] All costs are presented at 2014 values. We used the purchasing power parity conversion factor to convert cost values to US\$, with US\$ 1 equal to 3.51 Chinese yuan.[@R38]

### Effectiveness of screening

We used the sensitivity (probability of positive diagnosis if diseased) and specificity (probability of negative diagnosis if not diseased) values from an earlier study[@R29] that enrolled 3062 Chinese women (average age, 45 years) at risk of breast cancer. 11 screening modalities were compared, which are different combinations of clinical breast examination, mammography and ultrasound.****We varied the estimates in the sensitivity analyses in case of any variation in diagnostic performance due to the age of the screened population.

### QALYs

QALY is a measurement that reflects both length of life and health-related quality of life. It is calculated as the product of the utility score of a particular state of health, defined as a dimensionless number between 1 (perfect health) and 0 (death), and the number of years lived. We identified the utility scores for patients at stage I, II, III and IV from a cross-sectional survey conducted as part of the screening programme,[@R30] in which breast cancer patients across 13 Chinese provinces completed EuroQol five-dimensional questionnaires.

False-positive results could be argued to undermine quality of life due to psychological distress incurred;[@R39] a systematic review estimated a utility decrement (disutility) of 11--34% for false-positive results.[@R31] We estimated a loss of 25% at baseline[@R40] and explored the uncertainty in the sensitivity analysis.

### Analysis

In agreement with the China Guidelines for Pharmacoeconomic Evaluations,[@R41] we conducted the analysis from a societal perspective. In agreement with these guidelines,[@R41] we discounted future costs and future benefits at 3%. We estimated the lifetime costs of screening and its effects in terms of QALY. We calculated the incremental cost--effectiveness ratios, defined as the difference in cost divided by the change in QALY. The willingness-to-pay threshold was estimated to be three times the gross domestic product (GDP) per capita in China in 2014 (US\$ 7683).[@R42] An incremental cost--effectiveness ratio of less than US\$ 23 050/QALY[@R41] is therefore an indication that the risk-based breast cancer screening for urban Chinese women aged 40--69 years, compared with no screening, is cost--effective.

To explore the effect of parameter uncertainty, we conducted one-way and probabilistic sensitivity analyses. In the one-way sensitivity analysis, we used the minimum and maximum estimates for effectiveness of screening, utility scores and costs. We varied each parameter individually to assess its impact on overall results. In the probabilistic sensitivity analysis, we varied all variables simultaneously to further explore model uncertainty. The input variables were specified as distributions: costs have a gamma distribution; QALY values follow a log-normal distribution; and sensitivity and specificity of screening follow a beta distribution as suggested in the literature.[@R43] By varying input parameters over their respective distributions, we obtained 1000 estimates of incremental costs and incremental effects. We then plotted the cost--effectiveness acceptability curves to show the proportion of simulations for which the intervention was cost--effective at different willingness-to-pay thresholds.

Other scenarios explored included: (i) the impact of screening every 3 years or every 5 years, compared with no screening; (ii) screening every year, but only 70% of the detected cases having access to breast cancer treatment; and (iii) screening women aged 45--69 years every 1, 3 and 5 years via mammography and ultrasound, compared with mammography alone (maintaining the original screening strategy for women aged 40--44 years).

Results
=======

Our model estimated 43 incident cases of breast cancer per 1000 women over a lifetime; 21 were detected via screening and 22 on presentation with symptoms. [Table 2](#T2){ref-type="table"} reports the discounted lifetime costs, QALYs and incremental cost--effectiveness ratios. Overall, the risk-based breast cancer screening yielded higher QALYs compared with no screening (23.0129 QALYs versus 22.9843 QALYs), but was more expensive than no screening (US\$ 335.43 versus US\$ 99.68). The baseline discounted incremental cost--effectiveness ratio was US\$ 8253/QALY, well below the threshold of US\$ 23 050/QALY, indicating that the risk-based breast cancer screening programme is cost--effective.

###### Modelled cost--effectiveness ratios of risk-based breast cancer screening programme in urban China, 2014

  Comparators                                                 Lifetime costs per case (US\$)   QALY      Incremental costs (US\$)   Difference in QALY   ICER (95% CI)^a^
  ----------------------------------------------------------- -------------------------------- --------- -------------------------- -------------------- ------------------------------
  **Baseline analysis**                                                                                                                                  
  No screening                                                99.68                            22.9843   --                         --                   --
  Annual screening                                            335.43                           23.0129   235.76                     0.0286               8 253 (6 170 to 11 483)
  **Screening programme variations versus no screening**                                                                                                 
  Screening every 3 years                                     184.67                           22.9971   84.99                      0.0127               6 671 (5 019 to 9 048)
  Screening every 5 years                                     152.09                           22.9919   52.41                      0.0076               6 917 (5 157 to 9 416)
  Annual screening, but only 70% of detected cases treated    324.17                           23.0043   224.49                     0.0200               11 223 (8 137 to 17 127)
  **Mammography only versus mammography and ultrasound^b^**                                                                                              
  Annual screening                                            306.41                           23.0115   −29.02                     −0.0014              21 246 (−172 049 to 168 866)
  Screening every 3 years                                     172.94                           22.9960   −11.73                     −0.0011              11 000 (−73 330 to 99 983)
  Screening every 5 years                                     145.37                           22.9912   −6.72                      −0.0007              9 366 (−114 804 to 98 149)

CI: confidence interval; ICER: incremental cost--effectiveness ratio; RR: relative risk; QALY: quality-adjusted life year; US\$ United States dollars.

^a^ Discounted at 3%.

^b^ For women aged 45--69 years. Screening regime for women aged 40--44 years remains unchanged.

Note: Some inconsistency arise in some value due to rounding.

The one-way sensitivity analysis ([Fig. 3](#F3){ref-type="fig"}) indicates that the costs, utility scores and effectiveness of screening have little individual influence on the cost--effectiveness of the programme. We found the incremental cost--effectiveness ratios to be lower than the threshold at both the upper and lower limits of these variables. The results of the probabilistic sensitivity analysis ([Fig. 4](#F4){ref-type="fig"}) show that, at the threshold of US\$ 23 050/QALY, nearly 100% of the simulations indicate that the risk-based breast cancer screening programme is cost--effective compared with no screening.
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![Probabilistic sensitivity analysis of modelled cost--effectiveness of risk-based breast cancer screening programme, urban China, 2014](BLT.18.207944-F4){#F4}

In the scenario analysis ([Table 2](#T2){ref-type="table"}), screening every 3 years and every 5 years achieves an incremental cost--effectiveness ratio of US\$ 6671/QALY and US\$ 6917/QALY, respectively. A scenario of annual screening, but where only 70% of detected cases are treated, yields a higher incremental cost--effectiveness ratio of US\$ 11 223/QALY, which is still lower than the threshold. We also found the scenario of both mammography and ultrasound for women aged 45--69 years, compared with mammography alone, to be cost--effective. However, in the probabilistic sensitivity analysis, the confidence intervals of the incremental cost--effectiveness ratios are very wide: an indication of considerable uncertainty.

Discussion
==========

The results indicate that compared with no screening, the risk-based breast cancer screening programme is cost--effective. The results prove to be robust in the sensitivity analyses when we varied the estimates for effectiveness of screening, utility scores and costs.

Our finding that high-risk population-based breast screening is cost--effective has implications for breast cancer control in other low- and middle-income countries. Previous studies have reported that population-based mammography screening is not economically attractive in countries, such as the Islamic Republic of Iran and Ghana, with incremental cost--effectiveness ratios of US\$ 389 184/QALY[@R12] and US\$ 12 908/QALY,[@R11] respectively. The Chinese screening programme is more likely to be cost--effective than other general population-based screening programmes, since the detection rate in the Chinese programme is higher (16%)[@R14] than in general screening programmes (e.g. 3% in the United States of America and 6% in New Zealand).[@R15]^,^[@R16] This finding is consistent with the study comparing risk-based breast cancer screening strategies with general programmes, reporting that risk-based strategies result in greater health benefits for a given cost.[@R44]

For high-risk women aged 45--69 years, our scenario analysis shows that the benefits of ultrasound in addition to mammography are considerably uncertain. The wide confidence intervals, indicating uncertainty in the incremental cost--effectiveness ratios, do not appear to justify the increased costs. A potential alternative to the current screening strategy could therefore be mammography screening alone for high-risk women aged 45--69 years, instead of both ultrasound and mammography.

Screening every 3 years is the most cost--effective frequency among alternatives. Compared with screening every year, screening every 3 years decreases the total costs significantly, but does not change the effects significantly. The results vindicate the 3-year screening interval for breast cancer in some countries, such as the United Kingdom of Great Britain and Northern Ireland.[@R5]

Our study explored the impact of access to treatment on the overall results, suggesting that the screening programme is less cost--effective if not all detected cases go on to receive treatment. In China, patients need to pay on average 34% of total medical costs;[@R45] this can limit access to medical treatment for some women who have been diagnosed with breast cancer. Some women may also decide not to seek medical treatment if they are not experiencing any pain or do not feel ill;[@R46] such delays in the onset of treatment can however lead to a poorer prognosis,[@R46] reducing the cost--effectiveness of a screening programme.

As with the previous models,[@R8] we adopted the Markov approach in our modelling. While costs and quality of life are provided in the publications by the Chinese screening programme,[@R30]^,^[@R32]^,^[@R34] no long-term follow-up data are available. We therefore used a mathematical model from age 40 years to death to reflect the differences in costs and effects. We also adopted a prior natural history model, meaning that women free of breast cancer first transition to ductal carcinoma in situ or stage I, followed by the remaining stages in sequence; in contrast, another study[@R47] used a model in which it is possible to progress from being free of breast cancer to stage IV. In addition, we calibrated our model to estimate the probability of symptoms by cancer stage, using the distribution of incidence cases reported in the Chinese Cancer Registry Annual Report 2012[@R3] in an unscreened population.

Further, we incorporated the decrements in health-related quality of life from false-positive screening results into our model. In this analysis, we used a loss of 25% at baseline and explored the uncertainty (11--34%). However, the utility loss from false--positive results[@R39] remains controversial. Although some argue that pathologically elevated levels of distress and anxiety are not apparent,[@R48] the relatively small number of studies means that the long-term effects of false-positive breast cancer screening are still unknown.[@R48] In this analysis we used estimates from studies based in the United Kingdom of Great Britain and Northern Ireland,[@R31]^,^[@R40] which might bias the cost--effectiveness results of the Chinese screening programme. However, we explored the uncertainty and the results proved to be robust through the sensitivity analyses.

Limitations of our study also include the assumption of high-risk women having a cancer risk index twice that of other women;[@R23] the real relative risk among high-risk women in urban China is still unknown. Further, the costs of questionnaires and clinical screening in this study are derived from the cost accounting of the screening programme; other implementation costs such as the identification of eligible women, the administration of risk questionnaires and other ancillary costs were not included. This may lead to an underestimation of costs and subsequently the cost--effectiveness. For progression rates between stages and the relative risk of invasive cancer from ductal carcinoma in situ, we used data from other countries and assumed the parameters were applicable to China. These factors require careful consideration and further research is required to reduce uncertainty.

We used three times the Chinese gross domestic product (GDP) per capita as the willingness-to-pay threshold in our cost--effectiveness analysis. Although GDP-based thresholds are commonly cited,[@R41] they have been critized.[@R49] Even if estimated accurately, GDP-based cost--effectiveness ratios, or other estimates of willingness to pay, do not provide information on affordability, budget impact or the feasibly of implementation. Although cost--effectiveness ratios are informative in assessing value for money, willingness-to-pay thresholds should therefore not be used alone as a decisions rule for priority setting. Local policy context must also be considered.[@R49]

In conclusion, our analysis provides economic evidence for the cost--effectiveness of risk-based breast cancer screening in urban China.
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